Pontifax (Israel) IV, L.P. — SEC Form 4 filings

SEC reporting owner CIK 1726039. 1 Form 4 filing on record with FilingPulse; latest filed 2025-10-17.

Transaction summary — filings shown

Covers all 1 filing on record, filed 2025-10-17 to 2025-10-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Keros Therapeutics, Inc. (KROS)10% owner14 legs · 4,787,331 sh · $84,975,125

Form 4 filings — Pontifax (Israel) IV, L.P.

FiledFormIssuerReported transactionsSource
2025-10-174Keros Therapeutics, Inc. (KROS)
jointly with Pontifax Management 4 G.P. (2015) Ltd., Pontifax (Cayman) IV L.P., Pontifax (China) IV L.P., Pontifax Late Stage Fund L.P., Pontifax Late Stage GP Ltd., Kariv Tomer, Nussbaum Ran
Sale (S): 2,284,612 @ $17.75 · Sale (S): 1,121,045 @ $17.75 · Sale (S): 1,226,412 @ $17.75 · Sale (S): 155,262 @ $17.75EDGAR

FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1726039 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →